Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04290676 · ClinicalTrials.gov registry record
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
A clinical trial, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- 527
- Enrollment target
NCT04290676: Completed study, sponsored by EyePoint Pharmaceuticals.
NCT04290676 is a clinical trial that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 527 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04290676 has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- 527 participants
- Enrollment target
Study Summary
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Primary Outcome
Of eyes with a record at postoperative day 8, percentage with anterior chamber cell grade 0. Cells in the anterior chamber of the eye are indicative of intraocular inflammation and are evaluated using a slit-lamp biomicroscope; a grade of 0 indicates that no inflammatory cells were visible in a 1 mm by 1 mm slit beam.
Interventions
- DRUG DEXYCU (dexamethasone intraocular suspension) 9%.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-05-01 |
What the finished NCT04290676 record still lists
NCT04290676 is an observational study that tracks outcomes without assigning an intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which DEXYCU (dexamethasone intraocular suspension) 9%. is the first listed.
NCT04290676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04290676 about?
NCT04290676 is a clinical study titled "DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001". Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
What is the current status of trial NCT04290676?
This trial is currently completed. The enrollment target is 527 participants. The study started on 2019-11-13. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT04290676?
The interventions under investigation include: DEXYCU (dexamethasone intraocular suspension) 9%. (DRUG).
Who is sponsoring clinical trial NCT04290676?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI